In 1990, the Human Genome Project (HGP) began with the primary goal of identifying the 20,000-25,000 genes in human DNA. Although this effort ended in 2003, it is still widely regarded in the scientific community as a monumental feat of coordination and discovery. The resulting information from this 13 year effort has provided a conceptual and technological foundation for a shift in medicine in the near future. Although the project has ended, the challenge of harnessing and applying the information still continues today.

Jacinto Convit World Organization (JCWO) is pleased to announce the publication of their latest work “Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment” in Oncotarget.

Out of the five cancer immunotherapy types listed above, JCWO’s research and development is in the domain of cancer vaccines. This work in immunotherapy began decades ago when Dr. Jacinto Convit successfully developed and applied therapeutic vaccines for Leprosy and Cutaneous Leishmaniasis, the latter being widely used in Venezuela and other Latin-American countries.

Summary of 2018 achievements for the Jacinto Convit World Organization.

Since its inception, the Jacinto Convit World Organization has strived to help the most vulnerable, be useful to others and work for humanity, by continuing to develop a breast cancer immunotherapy (vaccine) designed by Dr. Jacinto Convit during the last years of his life.